|
Volumn 7, Issue 5, 2001, Pages 1154-1162
|
Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: Immune responses and survival in palliative treatment
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIIDIOTYPIC ANTIBODY;
CA 125 ANTIGEN;
HYPERIMMUNE GLOBULIN;
MONOCLONAL ANTIBODY CA125;
TUMOR ANTIGEN;
UNCLASSIFIED DRUG;
ADULT;
ALLERGIC REACTION;
ARTICLE;
CANCER IMMUNOTHERAPY;
CANCER SURVIVAL;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
FEMALE;
HUMAN;
IMMUNE RESPONSE;
OVARY CARCINOMA;
PALLIATIVE THERAPY;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
RECURRENT CANCER;
VACCINATION;
ANTIBODIES, ANTI-IDIOTYPIC;
CA-125 ANTIGEN;
FEMALE;
HUMANS;
IMMUNITY;
IMMUNOTHERAPY;
MIDDLE AGED;
OVARIAN NEOPLASMS;
PALLIATIVE CARE;
RECURRENCE;
SURVIVAL RATE;
TUMOR CELLS, CULTURED;
|
EID: 0034900191
PISSN: 10780432
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (100)
|
References (28)
|